US Pharma MarketingElevance will leave D.C. this summer and is considering other markets to depart, executives said. The company outperformed Wall Street expectations in the second quarter — but not by much, and its stock fell accordingly.
Elevance shuts down D.C. Medicaid business, eyes additional exits after passable Q2
Elevance will leave D.C. this summer and is considering other markets to depart, executives said. The company outperformed Wall Street expectations in the second quarter — but not by much, and its stock fell accordingly.
Source: Healthcare Dive